|
 Speaking at the newspaper's annual Tech Live conference, Bancel also
said sufficient interim results from the study takes longer to get
and that the government's permission to use the vaccine may not come
until next year.
The first interim analysis of the vaccine's efficacy will happen
when 53 people in the entire study get symptomatic COVID-19, the
report said.
"That first analysis is likely to occur in November, but it's hard
to predict exactly which week because it depends on the cases, the
number of people getting sick," the report quoted Bancel as saying.
Bancel had told Financial Times https://www.ft.com/content/9b242ecc-3dce-4534-9171-cdf624468a2a
last month that Moderna would not be ready to apply for emergency
use of its COVID-19 vaccine before Nov. 25 at the earliest.
Bancel also highlighted that a ramping up of production is a
challenge. "If one ingredient is missing, we cannot make the
vaccine," as per the Journal's report.
[to top of second column] |
Moderna is on track to produce 20 million doses of its experimental vaccine by
the end of the year, the company had said last month, adding that 25,296
participants had enrolled out of a planned 30,000 in its late-stage study.
Drugmakers are racing to develop a COVID-19 vaccine, with more than 150
potential vaccines being developed and tested globally.
Besides Moderna, Pfizer Inc, and AstraZeneca Plc, among others, are
front-runners to develop the vaccine.
(Reporting by Anirudh Saligrama in Bengaluru; editing by Uttaresh.V)
[© 2020 Thomson Reuters. All rights
reserved.] Copyright 2020 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content. |
